Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

ID Number 15-2014

Principal Investigator(s)
Charissa Chang

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to find out whether ramucirumab can help patients with liver cancer.  Ramucirumab is an experimental drug because it is still being tested and not yet approved to treat liver cancer.  However, the FDA has allowed the use of this drug for research.

Contact Information
Hoda Bashir
(212) 824-7309

Recruiting Patients: Yes